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ABSTRACT
Background Disruption of granulocyte/macrophage
colony-stimulating factor (GM-CSF) signalling causes
pulmonary alveolar proteinosis (PAP). Rarely, genetic
defects in neonatal or infant-onset PAP have been
identified in CSF2RA. However, no report has clearly
identified any function-associated genetic defect in
CSF2RB.
Methods and results The patient was diagnosed with
PAP at the age of 36 and developed respiratory failure.
She was negative for GM-CSF autoantibody and had no
underlying disease. Signalling and genetic defects in
GM-CSF receptor were screened. GM-CSF-stimulated
STAT5 phosphorylation was not observed and GM-CSF-
Rbc expression was defective in the patient’s blood cells.
Genetic screening revealed a homozygous, single-base
deletion at nt 631 in exon 6 of CSF2RB on chromosome
22, which caused reductions in GM-CSF dependent
signalling and function. Both parents, who were second
cousins, showed no pulmonary symptoms, and had
normal GM-CSF-signalling, but had a CSF2RB allele with
the identical deletion, indicating that the mutant allele
may give rise to PAP in an autosomal recessive manner.
Conclusions This is the first report identifying a genetic
defect in CSF2RB that causes deficiency of GM-CSF-Rbc
expression and impaired signalling downstream. These
results suggested that GM-CSF signalling was
compensated by other signalling pathways, leading to
adult-onset PAP.
INTRODUCTION
Pulmonary alveolar proteinosis (PAP) is a rare lung
disease in which lipoproteinaceous material is
accumulated in the alveoli and terminal bronchioles,
resulting in the development of respiratory failure.1
PAP is clinically divided into three distinct forms:
autoimmune, secondary and hereditary PAP.1
Autoimmune PAP is associated with the disruption
of granulocyte/macrophage colony-stimulating
factor (GM-CSF) signalling caused by high levels
of GM-CSF autoantibodies in the lung.2 3 Very
rarely, there are unclassified cases in which neither
GM-CSF autoantibodies nor underlying diseases are
confirmed.4 Of significance is the fact that mutant
mice deficient in GM-CSF or its receptor spontane-
ously develop PAP5 6 and some hereditary cases
exhibit defects in GM-CSF receptor (GM-CSF-R)
expression.7 8
GM-CSF-R is composed of the binding a chain
and the common b chain, which is also utilised by
interleukin-3 (IL-3) and IL-5. Binding of GM-CSF
initiates the Jak2, STAT5 and PI3K/Akt pathways.
Recently, two groups reported mutations in the
coding region of the GM-CSF-Ra gene (CSF2RA) in
hereditary PAP cases, which is located in the
pseudoautosomal region of PAR1 on the X and Y
chromosomes.7 8
Dirksen et al reported GM-CSF-R bc deficiency in
four patients with PAP diagnosed during the
neonatal to infant period. In one patient, a point
mutation in CSF2RB resulted in an amino acid
change at codon 602 from proline to threonine.9
However, this mutation is now known as a single
nucleotide polymorphism in normal subjects10
(NCBI SNP Database ID rs1801122; http://www.
genecards.org/), and thus, no report has clearly
identified gene defects in CSF2RB disrupting
GM-CSF signalling. Here, we describe the first
adult-onset case with a single-base deletion in exon
6 of CSF2RB, resulting in severe reductions in




This study was approved by the institutional
review boards of Nagasaki University and Niigata
University. Written informed consent was obtained
from the patient, her parents and all control
volunteers. Blood mononuclear cells were collected
from the subjects. Genetic counselling was
performed for the patient and her parents before
and after genetic analyses.
GM-CSF autoantibody measurement
GM-CSF autoantibody concentrations in the serum
and bronchoalveolar lavage fluid (BALF) were
measured by ELISA as described previously.4
Isolation of blood mononuclear cells and monocytes
Heparinised blood was obtained and blood mono-
nuclear cells were prepared by density gradient
centrifugation using Lymphoprep (Axis-Shield,
Oslo, Norway). To isolate CD14 positive mono-
cytes from blood mononuclear cells, human CD14
microbeads (MACS; Miltenyi Biotec, Auburn,
California, USA) were applied for magnetic sorting.
Differentiation of monocytes to macrophages in
vitro
Peripheral blood monocytes from a control subject
and the patient were cultured in a 24-well culture
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plate (BD Falcon, Franklin Lakes, New Jersey, USA) at 13105 cells
per well with 10 ng/ml of recombinant human GM-CSF
(Leukine, Berlex, Seatle, Washignton, USA) in Dulbecco’s Modi-
fied Eagle Medium (DMEM) containing 10% heat-inactivated
fetal bovine serum (FBS), 2 mM L-glutamine, 100 mg/ml strep-
tomycin and 100 U/ml penicillin in a humidified atmosphere of
5% CO2 at 378C. Morphological changes were evaluated after
5e14 days under phase contrast microscopy.
GM-CSF clearance assay
To assess receptor-mediated binding and uptake of exogenous
GM-CSF, blood mononuclear cells from the patient and control
volunteer were cultured in 24-well culture plates at 13106 cells
per well in DMEM containing 10% heat-inactivated FBS, 2 mM
L-glutamine, 100 mg/ml streptomycin and 100 U/ml penicillin
in a humidified atmosphere of 5% CO2 at 378C. Recombinant
human GM-CSF was added at a concentration of 100 pg/ml.
Subsequently, GM-CSF concentration in the supernatant of each
well was measured by ELISA (R&D Systems, Minneapolis,
Minnesota, USA), as previously described.7
Immunoblotting
Blood mononuclear cells were cultured on 24-well culture plates
at 53105 cells per well. Cells were incubated with GM-CSF
(0e1000 ng/ml) or IL-3 (0e10 ng/ml) for 15 min. Lysed protein
extracts were separated by sodium dodecylsulphate poly-
acrylamide gel electrophoresis, transferred to a polyvinylidene
fluoride (PVDF) membrane, and assessed by standard western
blotting procedures, as previously described.7 Primary antibodies
used for detection included anti-human GM-CSF-Rbc (Santa
Cruz Biotechnology, Santa Cruz, California, USA), anti-human
GM-CSF-Ra, anti-human STAT5 (Santa Cruz Biotechnology),
and anti-human phosphor-STAT5 (Millipore, Billerica, Massa-
chusetts, USA) antibodies. Peroxidase labelled anti-rabbit IgG
antibody (Sigma-Aldrich, St Louis, Missouri, USA) was used as
second antibody and visualised with ECL plus (GE Healthcare,
Waukesha, Wisconsin, USA). To enhance the signal, immuno-
reactions enhancer solution (Can Get Signal, TOYOBO, Osaka,
Japan) was used according to the manufacturer ’s instructions.
Actin was measured as a loading control for each sample using
anti-actin antibody (Santa Cruz Biotechnology).
Flow cytometry
CD11b expression of neutrophils was analysed by flow cytom-
etry (FACSCalibur, Beckton Dickinson, Franklin Lakes, New
Jersey, USA) as previously described.7 Briefly, heparinised whole
blood was collected and incubated in the absence or presence of
10 mg/ml human GM-CSF. Blood was incubated with a phyco-
erythrin (PE) conjugated mouse anti-human CD11b (BD Phar-
mingen, Franklin Lakes, New Jersey, USA) and a fluorescein
isothiocyanate (FITC) conjugated mouse anti-human CD16 (BD
Pharmingen). Each triplicate sample was analysed. Expression
of GM-CSF receptors was analysed using anti-human CD116
(GM-CSF-Ra) (eBioscience, San Diego, California, USA) and
anti-human CD131 (common b) (eBioscience).
Reverse transcription PCR
Total RNA was extracted from blood mononuclear cells using
RNA Easy Plus Mini Kit (QIAGEN, Hilden, Germany) and
was reverse transcribed with random hexamer primers using
the SuperScript III First-Strand Synthesis System for reverse
transcription (RT)-PCR (Invitrogen, Carlsbad, California, USA).
The cDNAs were subjected to semi-quantitative RT-PCR anal-
ysis using PrimeSTAR GXL DNA polymerase (TaKaRa Bio,
Otsu, Japan) with CSF2RA-specific primer (supplementary
table 2).
Nucleotide sequencing
PCR products were purified using QIAquick DNA extraction kit
(QIAGEN) and subjected to nucleotide sequencing using BigDye
Terminator V3.1 cycle sequencing kit (Applied Biosystems,
Foster City, California, USA) and CSF2RB-specific primer
(supplementary table 2).
Array-CGH
Array-comparative genomic hybridisation (aCGH) analysis was
performed using the Agilent 105AWhole Human Genome Oligo
Microarray kit according to the manufacturer ’s protocol
(Agilent Technologies, Palo Alto, California, USA). Genomic
DNA was extracted from peripheral blood using the QIAquick
DNA extraction kit (QIAGEN).
RESULTS
In 2000, a 36-year-old woman, previously healthy, with normal
chest radiograph at a health check-up 1 year earlier, gradually
developed dyspnoea on exertion. She was diagnosed as having
PAP by typical findings on chest radiography (figure 1A), bron-
choalveolar lavage (BAL), and lung histopathological examina-
tion (figure 1B). She had undergone whole lung lavage (WLL) five
times within 4 years and had subsequently started home oxygen
therapy. In 2005, the arterial blood gas analysis on room air
showed a PaO2 of 44.8 mm Hg. Her clinical parameters and
course are summarised in supplementary figure 1 and supple-
mentary table 1, respectively. Bone marrow cells showed mild
hypocellularity with normal cell differentials and a normal
karyotype of bone marrow cells. GM-CSF autoantibodies were
not detected in either the serum or BALF (supplementary table 1).
We decided to screen for GM-CSF signalling abnormalities
because GM-CSF concentration was extremely high in her
serum (124.8 pg/ml).7 The patient’s monocytes incubated with
GM-CSF failed to differentiate into macrophages with a viability
of less than 50% within 5 days (figure 1C). The baseline
expression of CD11b, a complement receptor of neutrophils,
was up-regulated in the patient compared with the control,
which was augmented by incubation with GM-CSF in the
control but not in the patient (figure 1D). Clearance of GM-CSF
by the patient’s peripheral blood mononuclear cells (PBMCs)
was impaired (figure 1E). We then analysed signal activated
by GM-CSF in PBMCs. When PBMCs were stimulated with
increasing concentrations of GM-CSF (0-1000 ng/ml), phos-
phorylated STAT5 was observed in the healthy control but
not in the patient’s PBMCs (figure 2A). Similarly, phosphory-
lated STAT5 was not observed in the IL-3-stimulated PBMCs,
suggesting defective signalling mediated by GM-CSF-Rbc
(figure 2B). Using flow cytometry, the expression of GM-CSF-Ra
on patient monocytes was comparable to the control; however,
expression of GM-CSF-Rbc was not detected (figure 2C). These
results were confirmed at mRNA level by RT-PCR (figure 2D)
and immunoblotting (figure 2E).
cDNA of CSF2RA reverse transcribed from the mRNA of the
patient PBMCs had no mutations or deletions (data not shown).
PCR amplicons for 14 exons of CSF2RB from patient PBMCs
appeared similar to the control in size and expression (figure 2F).
Screening of nucleotide sequences from the PCR amplicon for
each exon revealed a homozygous single-base deletion at nt 631
in exon 6 (accession number: AB573019) (figure 2G), causing
a frame shift that gave rise to a stop codon at nt 789 (supple-
mentary figure 2A). This deletion has not been reported in the
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SNPs database (UCSC Genome Browser Bioinformatics (http://
genome.ucsc.edu/) and the JSNP Japanese Single Nucleotide
Polymorphism Database (http://snp.ims.u-tokyo.ac.jp/index.
html)). The same deletion was recognised at the same codon in
the patient’s buccal mucosa, indicating that this change
occurred in the germ line (data not shown). Further evaluation
using array-comparative genomic hybridisation (aCGH)
demonstrated no interstitial deletion encompassing the region of
CSF2RB (supplementary figure 2B). Taken together with the
expression defect on PBMCs, mRNA harbouring a homozygous
premature termination codon in the patient’s CSF2RB gene may
be degraded by nonsense-mediated mRNA decay system.11
The nucleotide sequence of exon 6 in CSF2RB from the
PBMCs of both parents demonstrated heterozygous deletion at
the same codon as the patient (figure 2G); however, GM-CSF
stimulated STAT5 phosphorylation was normal (figure 2H). In
this regard, Suzuki et al reported a case with CSF2RA mutation
whose parents showed heterozygous mutations but normal
STAT5 phosphorylation under GM-CSF stimulation.7 12
Although CSF2RB and CSF2RA are different genes, it may
support our finding that a heterozygous mutation in GM-CSF
receptor genes does not cause the signalling defect. Furthermore,
according to the functional analysis in bc (/) mice, prolifer-
ating capacity of bone marrow cells under GM-CSF stimulation
was intact in heterozygous (+/) mice compared with that in
wild-type (+/+) mice.6 Although both parents were free from
any pulmonary disease, they had been second cousins with
a history of three miscarriages between them. Therefore, the
homozygous single-base deletion in CSF2RB was probably
inherited from both parents in an autosomal recessive manner.
DISCUSSION
This is the first report identifying a gene defect in CSF2RB
causing GM-CSF-Rbc deficiency and a signalling defect which
caused adult-onset hereditary PAP. In a previous report, flow
cytometry evaluation showed that four out of eight cases of
hereditary PAP had complete GM-CSF-Rbc deficiency, whereas
the remaining four cases showed reduced expression.9 All of
these diagnoses were made within the first 17 months of infancy
when all patients became symptomatic. Four patients with
a complete defect in GM-CSF-Rbc expression had severe respi-
ratory failure and required oxygen therapy. A point mutation
within CSF2RB was found in one patient, but was later recog-
nised to be present in 6% of 184 multinational normal subjects
as mentioned above.
Targeting deletion of GM-CSF-Rbc in mice has been shown to
give rise to the development of PAP between 6 and 14 weeks
after birth, which can be reversed by bone marrow trans-
plantation and haematopoietic reconstitution by 8e12 weeks
after the transplant.13 However, the defect in surfactant clear-
ance was significantly milder in CSF2RB targeted mice than in
GM-CSF deficient mice.14 In this regard, Ding et al hypothesised
that multiple intracellular signalling pathways are being
activated by GM-CSF binding to the GM-CSF-Ra alone.15
Thus, we speculate that the onset of PAP in the present case
might have been delayed by the signals from extremely elevated
GM-CSF in the lung, which was conveyed through GM-CSF-Ra.
Alternatively, some factors other than GM-CSF in the lung may
have compensated for the function of alveolar macrophages.
This was supported by the presence of mild leukocytosis on
admission and remarkably increased M-CSF levels in BALF, in
Figure 1 Pulmonary alveolar
proteinosis (PAP) diagnosis and
granulocyte/macrophage colony-
stimulating factor (GM-CSF) functional
analysis on leucocytes. (A) Chest high-
resolution CT demonstrating diffuse
homogenous ground-grass opacity and
crazy-paving appearance. (B) Section of
lung biopsy specimen stained with H&E,
demonstrating accumulation of
amorphous eosinophilic materials in
alveolar space (total magnification
403). Bar: 1.0 mm. (C) Phase contrast
microscopic images of monocytes from
the patient (right) or a control (left)
incubated with 10 ng/ml of GM-CSF for
5 days. Results shown are
representative of independent
experiments. (D) Flow cytometry
analyses for the expression of CD11b on
neutrophils from a control (upper) and
the patient (lower) incubated with (right)
or without (left) 10 mg/ml GM-CSF.
Results shown are representative of
independent experiments. (E) Time
course for absorption of exogenous GM-
CSF by peripheral blood mononuclear
cells (PBMCs) from the patient or
a control subject. Cells were incubated
as described in methods section.
Results are expressed as a percentage
of initial GM-CSF concentration. Data
are expressed as mean6SE. GM-CSF in
the culture supernatant was unchanged up to 48 h in the patient PBMCs, whereas it was rapidly decreased in the control, indicating that GM-CSF was
not absorbed by the patient’s cells.
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the absence of infectious disease. In this regard, the late onset of
PAP in the present case was distinctive and unique among bc
deficiency.
Taking the previous report into consideration,7 the detection
of phosphorylated STAT5 in blood mononuclear cells stimulated
with GM-CSF and/or IL-3 is likely to be a useful and convincing
method of screening for defects in GM-CSF-Ra signalling. This
case had some similarities of phenotype of PAP and molecular
biomarkers (serum GM-CSF, serum SP-D, GM-CSF in BAL,
M-CSF in BAL, CD11b SI, STAT5 phosphorylation, and
GM-CSF clearance) with CSF2RA mutations cases.12 Increased
GM-CSF levels in BALF and serum are important markers since
autoimmune PAP is typically characterised by neutralisation of
GM-CSF in the lung. Thus, an elevated serum free GM-CSF level
is useful in distinguishing between autoimmune and GM-CSF
receptor dysfunction PAP.16
Bone marrow transplantation would represent the most
effective treatment for our case. In this regard, Dirksen et al
reported that allogeneic bone marrow transplantation for
a patient with acute myelogenous leukaemia successfully led
to remission of secondary PAP.17 Fukuno et al described a case
of PAP secondary to myelodysplastic syndrome that resolved
after successful cord blood transplantation.18 Replacement
of impaired alveolar macrophages with stem cell derived
normal alveolar macrophages might correct the defect seen
in PAP. However, the safety and efficacy of bone marrow or
cord blood transplantation for this patient should be further
evaluated.19
Figure 2 Effect of granulocyte/
macrophage colony-stimulating factor
(GM-CSF) on functions of leucocytes,
and expression and genetic analyses of
GM-CSF-Rbc. (A) GM-CSF stimulated
phosphorylation of STAT5 in peripheral
blood mononuclear cells (PBMCs).
PBMCs from the patient or a control
subject were incubated with GM-CSF
(0e1000 ng/ml). Phosphorylated STAT5
(pSTAT5) was detected by western
blotting. As positive controls, total
STAT5 (STAT5) and actin were
detected. Results shown are
representative of independent
experiments. (B) IL-3 stimulated
phosphorylation of STAT5 in PBMCs
was evaluated by western blotting.
PBMCs from the patient or a control
subject were incubated with IL-3
(0e10 ng/ml). Results shown are
representative of independent
experiments. (C) Flow cytometry
analysis for the expression of GM-CSF-
Ra and bc on monocytes from a control
(upper) and the patient (lower). (D) RT-
PCR analysis of mRNA in PBMCs from
a control (left) or the patient (right) using
primers specific for cDNA of CSF2RA
(lower) or CSF2RB (upper). (E) Detection
of GM-CSF-Rbc (upper), a (middle) and
actin (lower) on PBMCs by western
blotting from a control (left) and the
patient (right) using anti-GM-CSF-Rbc,
a and actin antibodies, respectively. No
band was observed in the patient (right
lane) at the position of band for GM-
CSF-Rb which was detected in the
control (left lane), whereas bands for
GM-CSF-Ra and actin were clearly
detected in both the patient and the
control. Enhanced chemiluminescence
was used for the detection of the signal.
Results shown are representative of
independent experiments. (F)
Comparison of PCR amplicons for the 14
exons (exon1e14) from genomic DNA
of CSF2RB between a control and the patient.
(G) Nucleotide sequence of CSF2RB from a control, the patient and patient’s parents, encoding nt 626e637(numbered relative to the initiation codon;
GenBank accession NM_000395). (H) GM-CSF stimulated phosphorylation of STAT5 in PBMCs. PBMCs from a control, the patient’s father and mother
were incubated with or without GM-CSF (10 ng/ml). pSTAT5 was detected by western blotting. As positive controls, total STAT5 and actin were
detected. Results shown are representative of independent experiments.
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